VYNE Therapeutics (NASDAQ:VYNE) Releases Earnings Results, Beats Expectations By $0.02 EPS

VYNE Therapeutics (NASDAQ:VYNE) posted its earnings results on Thursday. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.02, Zacks reports. VYNE Therapeutics had a negative return on equity of 75.03% and a negative net margin of 6,425.19%.The firm had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.13 million.

VYNE Therapeutics Stock Performance

VYNE traded down $0.00 during trading on Friday, hitting $0.35. The stock had a trading volume of 3,204,479 shares, compared to its average volume of 1,903,457. The company has a 50 day moving average price of $0.34 and a 200-day moving average price of $0.80. VYNE Therapeutics has a one year low of $0.28 and a one year high of $4.30.

Wall Street Analyst Weigh In

VYNE has been the subject of several research analyst reports. BTIG Research downgraded VYNE Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 31st. Weiss Ratings restated a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, October 8th. HC Wainwright downgraded shares of VYNE Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 30th. Finally, Lifesci Capital lowered shares of VYNE Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 30th. Three investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $6.25.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of VYNE. Adage Capital Partners GP L.L.C. raised its holdings in shares of VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares during the period. Jane Street Group LLC bought a new stake in shares of VYNE Therapeutics in the second quarter valued at $206,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of VYNE Therapeutics in the second quarter valued at $176,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.